RxDoctor Payments Data

Charles Emerson, MD

Family Medicine · Oxford, ALNPI 1124224753

Payments from drug & device makers

$889in general payments, 2019–2025

Across 52 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$395
  • Exact Sciences$56
  • Lilly USA, LLC$52
  • Shield Therapeutics Inc$50
  • GSK$40
  • AstraZeneca$38
  • plus $258 from 12 others

What the payments were for

  • Food & beverage$889100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$889 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$116,271
Medicare patients
430
Services billed
5,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$80,453
JanuviaSitagliptin Phosphate74$65,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$37,808
EliquisApixaban23$30,680
RybelsusSemaglutide13$25,439
OzempicSemaglutide27$23,495
VraylarCariprazine Hcl15$21,598
ShingrixVaricella-Zoster Ge/As01b/Pf78$17,068
AbrysvoRsv Vacc, Pref A And Pref B/Pf35$10,880
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$10,237
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,550
ArexvyRsvpref3 Antigen/As01e/Pf20$6,054
Boostrix TdapDiphth,pertuss(Acell),tet Vac88$6,025
Diclofenac Potassium71$4,664
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$52$80,45376 claims
MerckJanuvia, Janumet$36$69,10688 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$40$60,929143 claims
Novo NordiskRybelsus, Ozempic$395$48,93440 claims
AbbVieVraylar$13$21,59815 claims
Boehringer IngelheimStiolto Respimat$12$10,23714 claims
AstraZenecaBreztri Aerosphere$38$9,55013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Oxford

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →